Stock Financial Ratios


XLRN / Acceleron Pharma Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price45.02
Volume350,600.00
Market Cap ($M)1,775.97
Enterprise Value ($M)1,366.16
Book Value ($M)225.60
Book Value / Share6.03
Price / Book4.95
NCAV ($M)231.50
NCAV / Share6.18
Price / NCAV5.53
Income Statement (mra) ($M)
Revenue27.77
EBITDA-66.11
Net Income-57.01
Balance Sheet (mrq) ($M)
Cash & Equivalents238.96
Cash / Share6.38
Assets381.28
Liabilities22.74
Quick Ratio9.09
Current Ratio9.09
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.25
Return on Assets (ROA)-0.23
Return on Equity (ROE)-0.25
Identifiers and Descriptors
CUSIP00434H108
Central Index Key (CIK)1280600
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
00434H908
000434H10
00434H958
Share Statistics
Common Shares Outstanding (M)45.24
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Raw Materials Per Share0.00
Retained Earnings Per Share-11.89
Long Term Debt Per Share0.00
Assets Current Per Share9.18
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Per Share10.19
Inventory Per Share0.00
Additional Paid In Capital Per Share21.48
Liabilities Current Per Share0.42
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Per Share0.19
Liabilities Per Share0.61
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Liabilities And Stock Equity Per Share10.19
Equity Per Share9.58
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash And Equivalents Per Share6.38
Accumulated Depreciation And Depletion Per Share0.00
Cash Per Share6.38
Property Plant And Equipment Net Per Share0.19
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00

Related News Stories

Acceleron Pharma: Updates To Thesis

2018-01-15 seekingalpha
I continue to look favorably on their collaboration with Celgene allowing them to take advantage of the larger firm´s considerable resources. (2-0)

BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018

2018-01-08 reuters
* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018 (2-0)

Your Daily Pharma Scoop: Lipocine Ahead Of Ad Com, Ohr's MAKO Study Fails, Zafgen Provides Update

2018-01-06 seekingalpha
Today we will discuss Lipocine (LPCN), which fell more than 10% on Friday ahead of the Ad Com for its lead product candidate TLANDO, an oral testosterone replacement therapy (TRT). (243-7)

Your Daily Pharma Scoop: Valeant Still Risky, Onconova Signs Agreement, Array Biopharma Announces Collaboration

2017-12-20 seekingalpha
Today we will discuss an article on Valeant (VRX) by Michael Wiggins De Oliveira, titled, “Valeant: I Was Serious – The Clock Is Ticking.” (334-4)

Cutting Edge Gene Therapies: Beta-Thalassemia Breakthroughs (Part I)

2017-12-12 seekingalpha
There are a collection of gene therapy companies which are rapidly trying to address rare diseases, a few of which have upcoming clinical products in this space. (117-0)

CUSIP: 00434H108